Home / Pharmacology / Enzymes / Kinases / MAPK Family / p38 MAPK / p38 MAPK Inhibitors / VX 702

VX 702

Cat. No. 3916 2 Citations Submit a Review Datasheet / COA / SDS

Discontinued Product

3916 has been discontinued.

View all p38 MAPK products.
Description: Orally active p38α and p38β inhibitor
Chemical Name: 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (1)
Pathways (1)
Biological Activity Technical Data Datasheets References

Biological Activity for VX 702

Orally active, ATP-competitive inhibitor of p38α MAPK; also inhibits p38β (KD values are 3.7 and 17 nM respectively).

Technical Data for VX 702

M. Wt 404.32
Formula C19H12F4N4O2
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 745833-23-2
PubChem ID 10341154
InChI Key FYSRKRZDBHOFAY-UHFFFAOYSA-N
Smiles NC(N(C3=C(F)C=CC=C3F)C1=CC=C(C(N)=O)C(C2=C(F)C=C(F)C=C2)=N1)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for VX 702

References are publications that support the biological activity of the product.

Din (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr.Opin.Investig.Drugs 7 1020 PMID: 17117592

Goldstein et al (2010) Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 53 2345 PMID: 19950901

Damjanov et al (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis. Arthrit.Rheumat. 60 1232

View Related Products by Target

View Related Products by Product Action

View all p38 MAPK Inhibitors

Keywords: VX 702, VX 702 supplier, VX702, orally, active, p38α, p38alpha, p38a, p38β, p38beta, p38b, inhibitors, inhibits, MAPK, Signaling, Signalling, Mitogen-Activated, Protein, Kinases, 479543-46-9, p38, 3916, Tocris Bioscience

2 Citations for VX 702

Citations are publications that use Tocris products. Selected citations for VX 702 include:

O'Sullivan et al (2016) Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions inhuman astrocytes. Journal of Neuroinflammation 13 189 PMID: 27549131

Baudet et al (2012) RNAi screen identifies MAPK14 as a druggable suppressor of human hematopoietic stem cell expansion. Blood 119 6255 PMID: 22555972

Reviews for VX 702

There are currently no reviews for this product. Be the first to review VX 702 and earn rewards!

Have you used VX 702?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

MAPK Signaling Scientific Review

MAPK Signaling Scientific Review

MAP kinase signaling is integral to the regulation of numerous cellular processes such as proliferation and differentiation, and as a result is an important focus of cancer and immunology research. Updated for 2016, this review discusses the regulation of the MAPK pathway and properties of MAPK cascades. Compounds available from Tocris are listed.

Pathways for VX 702

MAPK Signaling Pathway

MAPK Signaling Pathway

The mitogen-activated protein kinase pathway evokes an intracellular signaling cascade in response to extracellular stimuli such as heat and stress. It can influence cell division, metabolism and survival.